Cargando…

FHL2 expression and variants in hypertrophic cardiomyopathy

Based on evidence that FHL2 (four and a half LIM domains protein 2) negatively regulates cardiac hypertrophy we tested whether FHL2 altered expression or variants could be associated with hypertrophic cardiomyopathy (HCM). HCM is a myocardial disease characterized by left ventricular hypertrophy, di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedrich, Felix W., Reischmann, Silke, Schwalm, Aileen, Unger, Andreas, Ramanujam, Deepak, Münch, Julia, Müller, Oliver J., Hengstenberg, Christian, Galve, Enrique, Charron, Philippe, Linke, Wolfgang A., Engelhardt, Stefan, Patten, Monica, Richard, Pascale, van der Velden, Jolanda, Eschenhagen, Thomas, Isnard, Richard, Carrier, Lucie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215105/ https://www.ncbi.nlm.nih.gov/pubmed/25358972 http://dx.doi.org/10.1007/s00395-014-0451-8

Ejemplares similares

Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy
por: Schlossarek, Saskia, et al.
Publicado: (2014)

Translational investigation of electrophysiology in hypertrophic cardiomyopathy
por: Flenner, Frederik, et al.
Publicado: (2021)

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model
por: Friedrich, Felix W., et al.
Publicado: (2015)

Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue
por: Kresin, Nico, et al.
Publicado: (2019)

Novel FHL1 Mutation Associated With Hypertrophic Cardiomyopathy, Sudden Cardiac Death, and Myopathy
por: Binder, M. Scott, et al.
Publicado: (2020)

Scientists on the spot: Relaxing the heart in hypertrophic cardiomyopathy
por: Gladka, Monika M, et al.
Publicado: (2023)

Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
por: de Boer, Rudolf A., et al.
Publicado: (2022)

Association of Asymmetric Dimethylarginine and Diastolic Dysfunction in Patients with Hypertrophic Cardiomyopathy
por: Cordts, Kathrin, et al.
Publicado: (2019)

A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
por: Thottakara, Tilo, et al.
Publicado: (2021)

Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes—a systematic review
por: Eschenhagen, Thomas, et al.
Publicado: (2018)

The Roles of FHL3 in Cancer
por: Huang, Zhenjun, et al.
Publicado: (2022)

Novel FHL1 mutation variant identified in a patient with nonobstructive hypertrophic cardiomyopathy and myopathy – a case report
por: Giucă, Adrian, et al.
Publicado: (2020)

Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
por: Prondzynski, Maksymilian, et al.
Publicado: (2019)

FHL1 adds some muscle
por: Short, Ben
Publicado: (2008)

Orthostatic Blood Pressure Test for Risk Stratification in Patients with Hypertrophic Cardiomyopathy
por: Münch, Julia, et al.
Publicado: (2015)

An Upstream Hfq Binding Site in the fhlA mRNA Leader Region Facilitates the OxyS-fhlA Interaction
por: Salim, Nilshad N., et al.
Publicado: (2010)

Src turns FHL1 to the dark side
por: Short, Ben
Publicado: (2018)

Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice
por: Gedicke-Hornung, Christina, et al.
Publicado: (2013)

Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
por: Stücker, Sabrina, et al.
Publicado: (2017)

Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
por: Mearini, Giulia, et al.
Publicado: (2013)

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes
por: Prondzynski, Maksymilian, et al.
Publicado: (2017)

Molecular autopsy and family screening in a young case of sudden cardiac death reveals an unusually severe case of FHL1 related hypertrophic cardiomyopathy
por: Gaertner‐Rommel, Anna, et al.
Publicado: (2019)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL)
por: Merli, Pietro, et al.
Publicado: (2020)

Glucose-mediated insulin secretion is improved in FHL2-deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes
por: Habibe, Jayron J., et al.
Publicado: (2022)

S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue
por: Braumann, Simon, et al.
Publicado: (2018)

FHL1 protein isoforms in Emery-Dreifuss muscular dystrophy
por: Ziat, Esma, et al.
Publicado: (2015)

Extent of late gadolinium enhancement in patients with hypertrophic cardiomyopathy in correlation with serum MMP9 as an indicator of myocardial fibrosis
por: Avanesov, Maxim, et al.
Publicado: (2014)

The LIM-only protein FHL2 interacts with β-catenin and promotes differentiation of mouse myoblasts
por: Martin, Bernd, et al.
Publicado: (2002)

Epigallocatechin-3-Gallate Accelerates Relaxation and Ca(2+) Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice
por: Friedrich, Felix W., et al.
Publicado: (2016)

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Aggresome–Autophagy Involvement in a Sarcopenic Patient with Rigid Spine Syndrome and a p.C150R Mutation in FHL1 Gene
por: Sabatelli, Patrizia, et al.
Publicado: (2014)

FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia
por: Pašaliç, Z, et al.
Publicado: (2011)

FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy
por: Lee, Jen Y., et al.
Publicado: (2015)

MicroRNA-663 Regulates Melanoma Progression by Inhibiting FHL3
por: Liu, Saijun, et al.
Publicado: (2020)

LIM-only protein FHL2 attenuates vascular tissue factor activity, inhibits thrombus formation in mice and FHL2 genetic variation associates with human venous thrombosis
por: Kroone, Chantal, et al.
Publicado: (2020)

Regional myocardial function at preclinical disease stage of hypertrophic cardiomyopathy in female gene variant carriers
por: Parbhudayal, Rahana Y., et al.
Publicado: (2021)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre‐birth
por: Garcia‐Canadilla, Patricia, et al.
Publicado: (2019)

Deficiency in the LIM-only protein Fhl2 impairs skin wound healing
por: Wixler, Viktor, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9p5e69gpf2rbslh7taclppqolu